People infected with HIV must take antiretroviral drugs for life. But engineered antibodies appeared to suppress the virus ...
In the study, a once-daily, single-tablet combination of bictegravir and lenacapavir was as effective as Gilead's existing ...
Stacker on MSN
Achieving lasting remission for HIV
Knowable Magazine reports on breakthroughs in HIV treatment; engineered antibodies show promise for long-term control, ...
Gilead Sciences, Inc. (Nasdaq: GILD) today announced positive topline results from the Phase 3 ARTISTRY-2 trial. The ...
News Medical on MSN
Researchers See Dramatic Drop in HIV-Infected Immune Cells in Patient After Cancer Treatment Received
Paper in @jclinicalinvest (bit.ly/497z6jo) by @HopkinsMedicine @JHUMed_ID finds patient living w/ #HIV has dramatic drop in ...
Gilead Sciences said its in-development HIV treatment met the primary endpoint of a recent late-stage clinical trial. The biopharmaceutical company said Monday that the treatment, a once-daily single ...
UCSF researchers have found a treatment for HIV that shows potential as a long-term solution for the chronic disease that, up ...
A small UCSF study has found that a combination of vaccines, antibodies, and immune-activating drugs helped some HIV-positive ...
The tools to stop the spread of HIV are readily available, but experts said they're not getting to the right people.
Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback